TriSalus Life Sciences Inc
TLSI
NASDAQ
Biotechnology
$5.27
USD
-0.36 (-6.39%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $351.59M
Volume 113.8K
Revenue
$45.08M
TTM
+25.2%
YoY
Gross Margin
86%
TTM
+1.3%
YoY
Net Income
$-28.21M
TTM
+9.5%
YoY
Operating Cash Flow
$-22.80M
TTM
+19.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 11.2 | 11.6 | 13.2 | 8.9 | 11.4 |
YoY Growth | +52.3% | +57.4% | +59.8% | -2.9% | +1.7% |
Cost of Revenue | 1.8 | 1.9 | 1.8 | 1.2 | 1.5 |
Gross Profit | 9.4 | 9.7 | 11.4 | 7.7 | 9.9 |
Selling, General & Administrative | 13.1 | 13.5 | 12.1 | 12.9 | 16.6 |
Other Operating Expenses | -0.7 | 0.0 | 0.0 | 0.0 | 1.0 |
Total Operating Expenses | 16.0 | 18.7 | 14.7 | 16.1 | 20.7 |
Operating Income | -6.6 | -9.0 | -3.3 | -8.4 | -10.8 |
EBITDA | -6.5 | -8.9 | -3.1 | -8.3 | -10.7 |
Other Income / Expense | -0.4 | -0.5 | -5.2 | 11.2 | 2.7 |
Total Other Income / Expense | -1.7 | -1.8 | -6.5 | 10.0 | 1.6 |
Income Before Income Taxes | -8.3 | -10.8 | -9.8 | 1.5 | -9.2 |
Income Taxes | -0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -8.3 | -10.8 | -9.8 | 1.5 | -9.2 |
Consolidated Net Income / Loss | -8.3 | -10.8 | -9.8 | 1.5 | -9.2 |
Net Income Attributable to Common Shareholders | -9.0 | -41.3 | -9.8 | 1.5 | -9.2 |
Basic EPS | -$0.27 | -$0.96 | -$0.21 | $0.03 | -$0.16 |
Diluted EPS | -$0.27 | -$0.96 | -$0.21 | $0.03 | -$0.16 |
Basic Shares Outstanding | 32.9M | 43.1M | 47.1M | 51.5M | 58.3M |
Diluted Shares Outstanding | 32.9M | 43.1M | 47.1M | 52.3M | 58.3M |